ProCE Banner Activity

CE / CME

Breaking Down Biologic Therapies in Moderate to Severe Atopic Dermatitis: Who, What, When, Why, and How?

Video

On-demand webcast of expert faculty presentation on the pathophysiology of and available biologic therapeutics for treating moderate to severe atopic dermatitis. 

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Released: December 02, 2024

Expiration: December 01, 2025

Share

Faculty

Sandri Johnson

Sandri Johnson, MSN, FNP-BC, DCNP

Dermatology Nurse Practitioner
Midtown Dermatology
Raleigh and Rocky Mount, North Carolina

Jonathan Silverberg

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Provided by

Provided by Partners for Advancing Clinical Education (PACE) in partnership with the Dermatology Education Foundation Dermalorian™ Webinar Series.

ProCE Banner

Supporters

This activity is supported by an educational grant from Lilly.

Lilly

Partners

Dermatology Education Foundation Dermalorian™ Webinar Series

ProCE Banner

Target Audience

This activity is intended for nurse practitioners and physician associates who care for patients with moderate to severe atopic dermatitis.

Program Learning Goal

The goal of this activity is to improve learners’ knowledge and competence of learners to effectively and safely use available and emerging biologic therapies to optimize clinical outcomes for patients with moderate to severe AD.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Evaluate the medical need, clinical rationale, and available clinical evidence on emerging biologic therapies for patients with moderate to severe AD

  • Identify all patient candidates for available and emerging biologic therapies for moderate to severe AD

  • Integrate recommended disease assessment measures into treatment advancement approaches for patients with moderate to severe AD

Disclosure

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Sandri Johnson, MSN, FNP-BC, DCNP

Dermatology Nurse Practitioner
Midtown Dermatology
Raleigh and Rocky Mount, North Carolina

Sandri Johnson, MSN, FNP-BC, DCNP: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Leo, Lilly, Sanofi/Regeneron, UCB; other financial or material support: Johnson & Johnson.

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Jonathan Silverberg, MD, PhD, MPH: consultant/advisor/speaker: AbbVie, Alamar, Aldena, Amgen, AOBiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GlaxoSmithKline, Incyte, Inmagene, Invea, Kiniksa, Leo Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi/Genzyme, Shaperon, Target RWE, Teva, Union.

Kristine Kucera, PA-C, MPAS, DHS: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Beiersdorf, Bristol-Myers Squibb, Janssen, Leo Pharma, Novartis, Sun Pharma, UCB.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1 hour. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 02, 2024, through December 01, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.

  2. Read the target audience, learning objectives, and faculty disclosures.

  3. View and study the content in its entirety.

  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Partners for Advancing Clinical Education (PACE) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. 

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1 contact hour, including 1 hour of pharmacotherapy credit.

Physician Associate Continuing Medical Education

Partners for Advancing Clinical Education (PACE) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until December 01, 2025. PAs should only claim credit commensurate with the extent of their participation.

IPCE Credit Designation

This activity was planned by and for the healthcare team, and learners will receive 1 Interprofessional Continuing Education (IPCE) credit for learning and change.